CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference
CytomX Therapeutics (Nasdaq: CTMX), a pioneer in masked, conditionally activated biologics, has announced its participation in the upcoming Barclays 27th Annual Global Healthcare Conference.
The company's CEO and chairman, Sean McCarthy, D.Phil., is scheduled to deliver a presentation on Wednesday, March 12, 2025, at 3:00 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the Events and Presentations section of CytomX's website at www.cytomx.com.
Additionally, the management team will be available for one-on-one meetings with registered conference attendees.
CytomX Therapeutics (Nasdaq: CTMX), un pioniere nei biologici mascherati e attivati condizionatamente, ha annunciato la sua partecipazione alla prossima 27ª Conferenza Annuale Globale sulla Salute di Barclays.
Il CEO e presidente dell'azienda, Sean McCarthy, D.Phil., è programmato per tenere una presentazione mercoledì 12 marzo 2025, alle 15:00 ET. Gli investitori e le parti interessate possono accedere a una trasmissione in diretta della presentazione attraverso la sezione Eventi e Presentazioni del sito web di CytomX all'indirizzo www.cytomx.com.
Inoltre, il team di gestione sarà disponibile per incontri individuali con i partecipanti registrati alla conferenza.
CytomX Therapeutics (Nasdaq: CTMX), un pionero en biológicos enmascarados y activados condicionalmente, ha anunciado su participación en la próxima 27ª Conferencia Anual Global de Salud de Barclays.
El CEO y presidente de la compañía, Sean McCarthy, D.Phil., está programado para ofrecer una presentación el miércoles 12 de marzo de 2025, a las 3:00 p.m. ET. Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de Eventos y Presentaciones en el sitio web de CytomX en www.cytomx.com.
Además, el equipo de gestión estará disponible para reuniones individuales con los asistentes registrados a la conferencia.
CytomX Therapeutics (Nasdaq: CTMX), 조건부 활성화 생물학의 선구자로, 다가오는 바클레이스 제27회 연례 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다.
회사의 CEO이자 회장인 Sean McCarthy, D.Phil.는 2025년 3월 12일 수요일 오후 3시(ET)에 발표를 할 예정입니다. 투자자 및 관심 있는 분들은 CytomX 웹사이트 www.cytomx.com의 이벤트 및 발표 섹션을 통해 발표의 실시간 웹캐스트에 접근할 수 있습니다.
또한, 경영진 팀은 등록된 컨퍼런스 참석자들과의 개별 회의를 위해 대기할 것입니다.
CytomX Therapeutics (Nasdaq: CTMX), un pionnier des biologiques masqués et activés de manière conditionnelle, a annoncé sa participation à la prochaine 27ème Conférence Annuelle Mondiale sur la Santé de Barclays.
Le PDG et président de l'entreprise, Sean McCarthy, D.Phil., doit faire une présentation le mercredi 12 mars 2025 à 15h00 ET. Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section Événements et Présentations du site Web de CytomX à l'adresse www.cytomx.com.
De plus, l'équipe de direction sera disponible pour des réunions individuelles avec les participants enregistrés à la conférence.
CytomX Therapeutics (Nasdaq: CTMX), ein Pionier in maskierten, bedingt aktivierten Biologika, hat seine Teilnahme an der bevorstehenden 27. jährlichen globalen Gesundheitskonferenz von Barclays angekündigt.
Der CEO und Vorsitzende des Unternehmens, Sean McCarthy, D.Phil., wird am Mittwoch, den 12. März 2025, um 15:00 Uhr ET eine Präsentation halten. Investoren und Interessierte können über den Bereich Veranstaltungen und Präsentationen auf der Website von CytomX unter www.cytomx.com auf einen Live-Stream der Präsentation zugreifen.
Darüber hinaus wird das Management-Team für Einzelgespräche mit registrierten Konferenzteilnehmern zur Verfügung stehen.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025, at 3:00 p.m. ET.
A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engagers, and immune modulators such as cytokines. CytomX’s clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) and armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers, including CRC, and was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com
FAQ
When is CytomX Therapeutics (CTMX) presenting at the Barclays Healthcare Conference 2025?
How can investors watch CytomX's (CTMX) Barclays conference presentation?
Will CTMX management be available for individual investor meetings at the Barclays conference?
Who will represent CTMX at the Barclays 27th Annual Global Healthcare Conference?
